Safety, efficacy and tolerability of Ribavirin-free, Sofosbuvir-Based regimens for the treatments of chronic hepatitis C in patients with End-Stage Renal Disease.

Trial Profile

Safety, efficacy and tolerability of Ribavirin-free, Sofosbuvir-Based regimens for the treatments of chronic hepatitis C in patients with End-Stage Renal Disease.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 May 2016

At a glance

  • Drugs Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 May 2016 New trial record
    • 17 Apr 2016 Interim results (n=33) presented at The International Liver Congress™ 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top